Indications for FENSOLVI:
Central precocious puberty.
<2yrs: not established. Give by SC inj on the abdomen, upper buttocks, or another location with adequate amounts of SC tissue; rotate inj sites. Avoid areas with brawny or fibrous tissue or locations that could be rubbed or compressed. ≥2yrs: 45mg once every 6 months. If inadequate response, consider alternative treatments.
Monitor for psychiatric symptoms. History of seizures/epilepsy, cerebrovascular disorders, CNS anomalies or tumors: risk of convulsions. Monitor hormonal effects after 1–2 months of starting therapy and as needed during treatment. Measure height every 3–6 months and monitor bone age periodically. Exclude pregnancy prior to initiation. Advise females of reproductive potential to use non-hormonal method of contraception during treatment. Nursing mothers.
Caution with concomitant drugs that are associated with convulsions (eg, bupropion, SSRIs).
Inj site pain, nasopharyngitis, pyrexia, headache, cough, abdominal pain, inj site erythema, nausea, constipation, vomiting, upper respiratory tract infection, bronchospasm, productive cough, hot flush; psychiatric events, convulsions.
Kit—1 (Syringe A: prefilled w. diluent + Syringe B: prefilled w. lyophilized pwd + safety needle)